Evidence map›Paper›PMID 39268605›Full record

ArticleAllergy2025

Expansion of phenotypically modified type 2 memory B cells after allergen immunotherapy.

Anouk von Borstel, Simone Reinwald, Pei M Aui, Craig I McKenzie, Nirupama Varese, P Mark Hogarth, Mark Hew, Robyn E O'Hehir, Menno C van Zelm

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anouk von BorstelDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-3605-7936
Simone ReinwaldDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-9001-9367
Pei M AuiDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-2314-9989
Craig I McKenzieDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-7070-620X
Nirupama VareseDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-9074-3710
P Mark HogarthImmune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0360-7890
Mark HewAllergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7498-0000
Robyn E O'HehirDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-3489-7595
Menno C van ZelmDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-4161-1919

Funding

National Health and Medical Research Council
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39268605
PMCPMC11891399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.